ArticleCureus2025
An Investigation Into the Hepatoprotective Properties of Berberis asiatica, Withania somnifera, and Their Combination in Streptozotocin-Nicotinamide-Induced Type II Diabetes Mellitus in Wistar Rats.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rising prevalence of type II diabetes mellitus (T2DM) has increased the risk of hepatic dysfunction, necessitating effective therapeutic interventions. Natural products, particularly
objectivesThis study investigates the hepatoprotective effects of BA, WS, and their polyherbal combination in streptozotocin-nicotinamide-induced T2DM in Wistar rats.
methodsSeventy-eight adult albino Wistar rats were divided into 13 groups, including normal control, disease control, and treatment groups, which received BA, WS, and a polyherbal combination (PHC) at varying doses (250, 500, and 1,000 mg/kg). Metformin and glimepiride served as standard treatments. Liver function was assessed through serum glutamic pyruvic transaminase (SGPT) and bilirubin levels, and histopathological analysis was performed.
resultsTreatment with BA, WS, and PHC significantly reduced SGPT and bilirubin levels compared to the disease control (p < 0.001). The PHC demonstrated superior efficacy, with higher doses (1,000 mg/kg) exhibiting results comparable to standard drugs. Histopathological analysis revealed reduced hepatocellular damage in treated groups, indicating preserved hepatic architecture.
conclusionBA and WS, individually and in combination, significantly attenuated liver dysfunction in diabetic rats. The synergistic effect of PHC presents a promising natural therapeutic approach for managing diabetes-induced liver damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.